celecoxib has been researched along with Colonic Polyps in 12 studies
Colonic Polyps: Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)." | 9.14 | The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010) |
| "Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents." | 7.77 | Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011) |
| "In the comparison of carcinogenesis, the percentage of normal tissue (i." | 5.40 | Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014) |
| "Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)." | 5.14 | The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010) |
| "Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents." | 3.77 | Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011) |
| "To use decision analysis to compare the cost-effectiveness of celecoxib to surveillance colonoscopy in 'average' risk patients who had undergone prior adenoma resection." | 3.71 | Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. ( Arguedas, MR; Heudebert, GR; Wilcox, CM, 2001) |
| "In the comparison of carcinogenesis, the percentage of normal tissue (i." | 1.40 | Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JY | 1 |
| Alam, F | 1 |
| Chung, SW | 1 |
| Park, J | 1 |
| Jeon, OC | 1 |
| Kim, SY | 1 |
| Son, WC | 1 |
| Byun, Y | 1 |
| Foreman, JE | 1 |
| Sorg, JM | 1 |
| McGinnis, KS | 1 |
| Rigas, B | 1 |
| Williams, JL | 1 |
| Clapper, ML | 1 |
| Gonzalez, FJ | 1 |
| Peters, JM | 1 |
| Lynch, PM | 1 |
| Ayers, GD | 1 |
| Hawk, E | 1 |
| Richmond, E | 1 |
| Eagle, C | 1 |
| Woloj, M | 1 |
| Church, J | 1 |
| Hasson, H | 1 |
| Patterson, S | 1 |
| Half, E | 1 |
| Burke, CA | 1 |
| Sagiv, E | 1 |
| Sheffer, M | 1 |
| Kazanov, D | 1 |
| Shapira, S | 1 |
| Naumov, I | 1 |
| Kraus, S | 1 |
| Domany, E | 1 |
| Arber, N | 1 |
| Thakkar, K | 1 |
| Fishman, DS | 1 |
| Gilger, MA | 1 |
| Couzin, J | 1 |
| Meyer, CH | 1 |
| Harris, RE | 1 |
| Nelson, NJ | 1 |
| Ziegler, J | 1 |
| Arguedas, MR | 1 |
| Heudebert, GR | 1 |
| Wilcox, CM | 1 |
| Chau, I | 1 |
| Cunningham, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Pilot Toxicity/Methods Validation Study of Celecoxib in Genotype-Positive Children With Familial Adenomatous Polyposis[NCT00685568] | Phase 1 | 22 participants (Actual) | Interventional | 2002-11-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Colonic Polyps
| Article | Year |
|---|---|
Colorectal polyps in childhood.
Topics: Adenomatous Polyps; Adolescent; Age of Onset; Celecoxib; Child; Child, Preschool; Colonic Polyps; Co | 2012 |
1 trial available for celecoxib and Colonic Polyps
| Article | Year |
|---|---|
The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Celecoxib; Child; Cohort Studies; Colonic Neoplasms | 2010 |
10 other studies available for celecoxib and Colonic Polyps
| Article | Year |
|---|---|
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Azoxymethane; Carci | 2014 |
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Blotting, Western; Celecoxib; Coloni | 2009 |
Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.
Topics: Adenocarcinoma; Celecoxib; Cell Cycle; Cell Transformation, Neoplastic; Colonic Polyps; Colorectal N | 2011 |
Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
Topics: Alzheimer Disease; Celecoxib; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; D | 2004 |
[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Costs a | 2005 |
Does the dose make the poison?
Topics: Celecoxib; Colonic Polyps; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2005 |
Celecoxib shown effective in preventing colon polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib | 2006 |
Cancer and arthritis share underlying processes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cell Transfo | 1998 |
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
Topics: Adenoma; Aged; Celecoxib; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Cost-B | 2001 |
Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
Topics: Adenomatous Polyposis Coli; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; | 2002 |